All News - Eli Lilly and Company
WEBRecent Press Releases. View All Press Releases. FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis. September 13, 2024. Lilly expands manufacturing footprint in Ireland with $1.8 billion investment.
Lilly.com | Eli Lilly and Company
WEBSep 13, 2024 · Press Releases. ALL CORPORATE FINANCIAL PRODUCT IMPACT ARCHIVE. New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis. September 25, 2024.
News Release - Eli Lilly and Company
WEBMay 13, 2022 · FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 …
News Release - Eli Lilly and Company
WEBMay 24, 2024 · Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history. Since 2020, the company has committed more than $18 billion to build, upgrade and acquire facilities in the U.S. and Europe. INDIANAPOLIS, May 24, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today …
News Release - Eli Lilly and Company
WEBApr 22, 2024 · INDIANAPOLIS and LINCOLNSHIRE, Ill., April 22, 2024 – Eli Lilly and Company (NYSE: LLY) and Nexus Pharmaceuticals, LLC today announced a definitive agreement for Lilly to acquire a manufacturing facility from Nexus, a leading sterile manufacturer in the pharmaceutical industry.
Lilly hits record high after Mounjaro fuels forecast raise, rival data
WEBAug 8 (Reuters) - Eli Lilly (LLY.N) on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares...
Lilly.com | Eli Lilly and Company
WEBSep 4, 2024 · INDIANAPOLIS , June 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI 's generative AI to invent novel antimicrobials to treat drug-resistant pathogens.
Eli Lilly prepares for as many as 5 new drug launches next year
WEBDec 13 (Reuters) - Eli Lilly and Co (LLY.N) said on Tuesday it hopes to launch as many as five new treatments next year that could drive growth through the decade as it bets on multi-billion...
Eli Lilly (LLY) earnings Q2 2024 - CNBC
WEBAug 8, 2024 · Excluding one-time items associated with the value of intangible assets and other adjustments, Eli Lilly posted earnings of $3.92 per share for the second quarter of 2024. The company posted ...
Eli Lilly and Company (LLY) Latest Stock News & Headlines
WEBGet the latest Eli Lilly and Company (LLY) stock news and headlines to help you in your trading and investing decisions.
Skip to content